Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Frontline Therapy in de Novo Multiple Myeloma Patients Under 65 (IFM2008)

This study has been completed.
Sponsor:
Collaborators:
Celgene Corporation
Janssen-Cilag Ltd.
Information provided by (Responsible Party):
University Hospital, Toulouse
ClinicalTrials.gov Identifier:
NCT01206205
First received: September 17, 2010
Last updated: June 11, 2014
Last verified: June 2014